RARE News

Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Lifshitz Law PLLC Announces Investigations of Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), Oracle Corporation (NYSE: ORCL), and BlackRock, TCP Capital Corp. (NASDAQ: TCPC)

RARE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 Ready to Announce with Confidence?

Lifshitz Law PLLC Announces Investigations of REGENXBIO Inc. (NASDAQ: RGNX), Kyndryl Holdings, Inc. (NYSE: KD), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)

Pomerantz LLP Advises Shareholders of Class Action Involving Ultragenyx Pharmaceutical Inc. – RARE

Ultragenyx Pharmaceutical Inc. Class Action: Levi & Korsinsky Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 – RARE

RARE DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - RARE

ULTRAGENYX URGENT DEADLINE: Bragar Eagel & Squire, P.C. Reminds Ultragenyx (NASDAQ:RARE) Investors of the April 6th Lead Plaintiff Deadline and Urges Investors to Contact the Firm

RARE FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026